Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma

International Journal of Cancer

Volumn 134, Issue 7, 2014, Pages 1758-1766

  Ghosh, Subrata K ^a   Yigit, Mehmet V ^a   Uchida, Masashi ^a   Ross, Alana W ^a   Barteneva, Natalie ^b   Moore, Anna ^a   Medarova, Zdravka ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

breast cancer; doxorubicin; nanodrug; pancreatic cancer; small interfering RNA

Indexed keywords

ANTI SURVIVIN SMALL INTERFERING RNA NANODRUG; ANTINEOPLASTIC AGENT; CASPASE 3; DOXORUBICIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; THERAPY EFFECT; TRIPLE NEGATIVE BREAST CANCER;

BREAST CANCER; DOXORUBICIN; NANODRUG; PANCREATIC CANCER; SMALL INTERFERING RNA;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; NANOPARTICLES; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84892577951     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28499     Document Type: Article

References (28)

1. Chew HK,. Medical management of breast cancer: today and tomorrow. Cancer Biother Radiopharm 2002; 17: 137-49.
2. Hardenbergh PH, Recht A, Gollamudi S, et al. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys 1999; 45: 69-72.
3. Smith L, Watson MB, O'Kane SL, et al. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther 2006; 5: 2115-20.
4. Ambrosini G, Adida C, Altieri DC,. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
5. Pennati M, Folini M, Zaffaroni N,. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28: 1133-9.
6. Fukuda S, Pelus LM,. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087-98.
7. Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006; 17: 597-604.
8. Sarela AI, Verbeke CS, Ramsdale J, et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002; 86: 886-92.
9. Morrison DJ, Hogan LE, Condos G, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26: 271-9.
10. Trabulo S, Cardoso AM, Santos-Ferreira T, et al. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharm 2011; 8: 1120-31.
11. Li Z, Yin PH, Yang SS, et al. Recombinant attenuated Salmonella typhimurium carrying a plasmid co-expressing ENDO-VEGI151 and survivin siRNA inhibits the growth of breast cancer in vivo. Mol Med Rep 2013; 7: 1215-22.
12. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007; 13: 372-7.
13. Kumar M, Yigit M, Dai G, et al. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res 2010; 70: 7553-61.
14. Hayes DF, Mesa-Tejada R, Papsidero LD, et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol 1991; 9: 1113-23.
15. Moore A, Medarova Z, Potthast A, et al. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004; 64: 1821-7.
16. Medarova Z, Pham W, Kim Y, et al. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer 2006; 118: 2796-802.
17. Medarova Z, Rashkovetsky L, Pantazopoulos P, et al. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 2009; 69: 1182-9.
18. Ghosh SK, Uchida M, Yoo B, et al. Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model. Int J Cancer 2013; 132: 1860-7.
19. Matito C, Mastorakou F, Centelles JJ, et al. Antiproliferative effect of antioxidant polyphenols from grape in murine Hepa-1c1c7. Eur J Nutr 2003; 42: 43-9.
20. Boren J, Brindle KM,. Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell Death Differ 2012; 19: 1561-70.
21. Blagosklonny MV, Robey R, Bates S, et al. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000; 105: 533-9.
22. Aliabadi HM, Mahdipoor P, Uludag H,. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells. Cancer Gene Ther 2013; 20: 169-77.
23. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92: 271-8.
24. Gamen S, Anel A, Perez-Galan P, et al. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res 2000; 258: 223-35.
25. Lu Y, Tatsuka M, Takebe H, et al. Involvement of cyclin-dependent kinases in doxorubicin-induced apoptosis in human tumor cells. Mol Carcinog 2000; 29: 1-7.
26. Hershman DL, Shao T,. Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park) 2009; 23: 227-34.
27. Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009; 20: 816-27.
28. Yin Q, Shen J, Chen L, et al. Overcoming multidrug resistance by codelivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters). Biomaterials 2012; 33: 6495-506.